Minoryx Therapeutics, based in Mataró (Barcelona), will also finance the activities necessary to be able to proceed with the approval of leriglitazone in the United States...
Minoryx has completed a Phase 3 trial with its drug candidate for a neurodegenerative orphan disease and the results are significant. The only downside is that...